



Vaccine Development and Immune Responses in Tuberculosis

Guest Editors:

Prof. Dr. Pere-Joan Cardona

Microbiology Department,
Hospital Universitari Germans
Trias i Pujol, Universitat
Autònoma de Barcelona,
Badalona, Catalonia, Spain

Prof. Dr. Petros C. Karakousis

Johns Hopkins School of
Medicine, Baltimore, MD, USA

Dr. Rasmus S. Mortensen

Department of Infectious
Immunology / TB Vaccine,
Statens Serum Institut, 2300
Copenhagen, Denmark

Deadline for manuscript
submissions:

closed (31 August 2021)

Message from the Guest Editors

Dear Colleagues,

Interest in the development of an effective TB has experienced an extraordinary growth in the last 20 years. Despite the numerous proposals that have emerged through these efforts, however, we have sadly seen limited success. Indeed, though several pivotal efficacy trials have begun, leading to a few victories, it appears that this field is in dire need of new approaches, a so-called “pink swan”—a term coined in the field five years ago—in order to find a definitive champion which is able to substitute the old BCG. This means that the design of new strategies should be able to integrate the newest knowledge in the natural history of *Mycobacterium tuberculosis* infection and the latest vaccine design approaches in fields beyond infectious diseases. This is why we invite authors to submit proposals with “out of the box” strategies.

Dr. Pere-Joan Cardona

Dr. Petros C. Karakousis

Dr. Rasmus S. Mortensen

Guest Editors





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious
Diseases, College of Veterinary
Medicine, University of Georgia,
Athens, GA 30602-7387, USA

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Author Benefits

Open Access: free for readers, with **article processing charges (APC)** paid by authors or their institutions.

High Visibility: indexed within **Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPus / SciFinder, and other databases.**

Journal Rank: JCR - Q1 (Immunology) / CiteScore - Q1 (Pharmacology (medical))

Contact Us

Vaccines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/vaccines
vaccines@mdpi.com